Loading
A phase 1/2 trial of cisplatin in colorectal cancer, run by Roswell Park Cancer Institute, now recruiting.
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases is a phase 1/2, interventional study registered as NCT03965234 by Roswell Park Cancer Institute, with a registry enrolment figure of 99 participants, started 2020-07-16 and due to reach its primary completion in 2029-05-25. Interventions recorded: Cisplatin; Isolated Chemotherapeutic Lung Perfusion; Metastasectomy. Conditions listed: Metastatic Bone Sarcoma; Metastatic Malignant Neoplasm in the Lung; Metastatic Soft Tissue Sarcoma; Metastatic Unresectable Sarcoma; Resectable Sarcoma; Colorectal Cancer. Primary outcome: Incidence of local toxicities (Phase I); Recommended phase II dose (Phase I); Local recurrence (Phase II). Colorectal eligibility wording from the registry: "* Colorectal carcinoma". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MRD / molecular residual disease testing, Platinum agents, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Platinum agents, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Platinum agents, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Platinum agents, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Platinum agents, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Platinum agents, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/